UNCY | Unicycive Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3732 - 0.4090
52 Week Range	0.2020 - 1.8180
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	971,705
Average Volume	2,474,948
Shares Outstanding	94,356,200
Market Cap	35,411,882
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-12

Valuation
Profitability
Growth
Health
P/E Ratio	-1.04
Forward P/E Ratio	N/A
EPS	-0.36
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	USA
Website	UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

UNCY's peers: ADTX, APM, APRE, CAPR, DRUG, CELZ, EVAX, EYEG, KPRX, LPCN, MBIO, PALI, QNRX, RVPH, SABS, SPRC, SRZN, TCBP, TENX, RNAZ, AMAM, CDIO, HILS, SQL, VYNE, OKYO, VRAX, ERNA, ICU, CMND

*Chart delayed

Analyzing fundamentals for UNCY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see UNCY Fundamentals page.

Watching at UNCY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on UNCY Technicals page.